News & Updates

Among patients with cardiovascular implantable electronic device (CIED) infection, only a few undergo device extraction, which lowers the risk of death, as shown in a study.

Treatment with aztreonam in combination with avibactam (ATM-AVI) results in favourable clinical response and is well tolerated in patients with complicated intra-abdominal infection (cIAI) and hospital-acquired or ventilator-associated pneumonia (HAP/VAP) due to Gram-negative bacteria, according to the results of the REVISIT study.

In a real-world study presented at IDWeek 2023, dalbavancin has been shown to be an effective treatment alternative for patients with invasive gram-positive infections.

Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.

Bivalent COVID-19 vaccine conferred protection against SARS-COV-2 infection among children and adolescents aged 5–11 years, according to a recent study presented at IDWeek 2023.